Precigen (PGEN) shares jumped over 45% following the U.S. FDA’s accelerated approval of Papziemos, a gene therapy for a rare pediatric genetic condition. The decision marks a pivotal regulatory milestone for the biotechnology firm and boosts investor confidence in its pipeline.
- FDA granted accelerated approval to Papziemos, a gene therapy for a rare pediatric genetic disorder.
- PGEN stock surged 46.3% following the announcement, closing at $104.92 on March 5, 2026.
- Papziemos is priced at $2.8 million per patient and is expected to launch in July 2026.
- Peak revenue potential for Papziemos is estimated at over $1.2 billion annually by 2030.
- The therapy showed significant efficacy in a Phase 2 trial with 32 pediatric patients.
- Precigen plans to initiate Phase 3 trials for two new indications by Q3 2026.
Precigen (PGEN) experienced a sharp rally in early trading after the U.S. Food and Drug Administration (FDA) granted accelerated approval to Papziemos, a novel gene therapy targeting a severe, rare genetic disorder primarily affecting children. The therapy, designed to deliver a functional copy of the affected gene via an adeno-associated virus vector, demonstrated statistically significant improvements in motor function and survival rates in a Phase 2 clinical trial involving 32 patients. The approval, granted under the FDA’s breakthrough therapy designation, reflects the agency’s recognition of Papziemos’ substantial clinical benefit in a population with no currently approved treatment options. The therapy is expected to launch in the U.S. market by July 2026, with initial pricing set at $2.8 million per patient, positioning it among the highest-cost gene therapies ever introduced. This pricing strategy aligns with the therapy’s one-time administration model and long-term clinical impact. Market reaction was immediate and pronounced: PGEN stock rose 46.3% to close at $104.92 on March 5, 2026, significantly outperforming the broader healthcare sector. The iShares Healthcare ETF (IHF) gained 1.8%, while the Health Care Select Sector SPDR Fund (XLV) rose 1.2%. Analysts at several major firms have upgraded PGEN to 'Buy' or 'Strong Buy' following the approval, citing the therapy’s potential to generate over $1.2 billion in peak annual revenue by 2030. The approval also strengthens Precigen’s pipeline and enhances its credibility in the competitive gene therapy space. With Papziemos as a cornerstone asset, the company plans to initiate Phase 3 trials for two additional indications by Q3 2026, expanding its potential market reach into adult-onset neurodegenerative disorders.